Original Articles 2005/6/7

Similar documents
Bad to the bones: treatments for breast and prostate cancer

Assessment and Treatment of Osteoporosis Professor T.Masud

Pharmacy Management Drug Policy

Postmenopausal osteoporosis is a systemic

OSTEOPOROSIS MANAGEMENT AND INVESTIGATION. David A. Hanley, MD, FRCPC

Fragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey

Pharmacy Management Drug Policy

Submission to the National Institute for Clinical Excellence on

Differentiating Pharmacological Therapies for Osteoporosis

Presenter: 翁家嫻 Venue date:

Osteoporosis/Fracture Prevention

Pharmacy Management Drug Policy

Breast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime

Integrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK

NAMS Practice Pearl. Use of Drug Holidays in Women Taking Bisphosphonates. Released April 1, 2013

Current Issues in Osteoporosis

Controversies in Osteoporosis Management

Skeletal Manifestations

Forteo (teriparatide) Prior Authorization Program Summary

Comparison of Bone Density of Distal Radius With Hip and Spine Using DXA

This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against

OSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO

Management of postmenopausal osteoporosis

Osteoporosis Screening and Treatment in Type 2 Diabetes

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS

July 2012 CME (35 minutes) 7/12/2016

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010

Effective Health Care

Breast Cancer and Bone Health. Robert Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield

Interpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm

Osteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK

1

Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases

Osteoporosis: Not Just for Women Anymore. Osteoporosis is characterized by low bone. By Lisanne G. Laurier, MD, PhD, FRCPC.

Osteoporosis: An Overview. Carolyn J. Crandall, MD, MS

Osteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.

Diagnosis of Vertebral Fractures by Vertebral Fracture Assessment

Does raloxifene (Evista) prevent fractures in postmenopausal women with osteoporosis?

Osteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011

Osteoporosis. Overview

Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC

Building Bone Density-Research Issues

Osteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis

From Fragile to Firm. Monika Starosta MD. Advocate Medical Group

Osteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT

Horizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329

FORTEO (teriparatide) INJECTION

Oral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis

Male osteoporosis: clinical approach and management in family practice

O. Bruyère M. Fossi B. Zegels L. Leonori M. Hiligsmann A. Neuprez J.-Y. Reginster

Prevalence of Osteoporosis p. 262 Consequences of Osteoporosis p. 263 Risk Factors for Osteoporosis p. 264 Attainment of Peak Bone Density p.

Osteoporosis - recent advances in diagnosis and treatment

DECADES OF PUBLISHED STUDIES have confirmed the

Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures

The Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD

Based on review of available data, the Company may consider the use of denosumab (Prolia) for the

denosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017

BAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008

Advanced DXA Using TBS insight

Current and Emerging Strategies for Osteoporosis

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study

Clinical Practice. Presented by: Internist, Endocrinologist

Hot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis

Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary

Appendix G How to start and expand Fracture Liaison Services

Official Positions on FRAX

Index. Rheum Dis Clin N Am 32 (2006) Note: Page numbers of article titles are in boldface type.

How to start and expand Fracture Liaison Services

Available online at ScienceDirect. Osteoporosis and Sarcopenia 1 (2015) 109e114. Original article

Name of Policy: Boniva (Ibandronate Sodium) Infusion

Osteoporosis is estimated to develop in 1 out of 4 women over the age of 50. Influence of bone densitometry results on the treatment of osteoporosis

Name of Policy: Zoledronic Acid (Reclast ) Injection

Annual Rheumatology & Therapeutics Review for Organizations & Societies

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

Endocrine Unit and Chair of Endocrinology Director Prof. Manuela Simoni. Hot topics in osteoporosis. How long to treat

C. S. H. Grace, K. W. B. Kelvin, C. T. Wei & T. B. Yeow

Drug Intervals (Holidays) with Oral Bisphosphonates

Bisphosphonate treatment break

Fractures: Epidemiology and Risk Factors. July 2012 CME (35 minutes) 7/24/ July12 1. Osteoporotic fractures: Comparison with other diseases

Objectives. Discuss bone health and the consequences of osteoporosis on patients medical and disability status.

Prevalence of vertebral fractures on chest radiographs of elderly African American and Caucasian women

Factors related to bone forming inadequate response to treatment (teriparatide/pth 1-84) in patients with severe osteoporosis. Preliminary results

Effect of Precision Error on T-scores and the Diagnostic Classification of Bone Status

Guideline for the investigation and management of osteoporosis. for hospitals and General Practice

What is Osteoporosis?

Long-term Osteoporosis Therapy What To Do After 5 Years?

SERMS, Hormone Therapy and Calcitonin

Osteoporosis challenges

Agenda. Adjuvant Bisphosphonates: Ready For Prime Time? The Osteoporosis Equation. Risk Factors for Osteoporosis. Charles L.

Ghada El-Hajj Fuleihan, MD,MPH.

Early release, published at on March 22, Subject to revision.

QCT BMD Imaging vs DEXA BMD Imaging

DXA scanning to diagnose osteoporosis: Do you know what the results mean?

BREAST CANCER AND BONE HEALTH

VERTEBRAL FRACTURES ARE THE

TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO

2017 Santa Fe Bone Symposium McClung

Collagen Crosslinks, Any Method

Transcription:

Original Articles 2005/6/7 Wilkinson JM, Eagleton AC, Stockley I, Peel NFA, Hamer AJ, Eastell R. Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: a randomised trial. J Ortho Research 2005:23;1-8 Gluer CC, Eastell R, Reid DM Kolta S. Reply Risk assessment and fracture discrimination by ultrasound: the debate continues. J Bone Min Res 2005, vol 20 : 3 ; 539-540 Siminoski K, Jiang G, Adachi JD.Eastell R. Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures. Osteo Int 2005, vol 16:403-410 Delmas P, van de Langerijt L, Watts NB, Eastell R,.. Cahall D for the IMPACT Study Group. Underdiagnosis of vertebral fractures is a worldwide problem: The IMPACT Study. J Bone Min Res 2005, vol 20:4,557-563 Wilkinson JM, Hamer AJ, Stockley I, Eastell R. Polyethylene wear rate and osteolysis: critical threshold versus continuous dose-response relationship. J Ortho Research 2005:23;520-525 Ingle BM, Machado AB, Pereda CA, Eastell R. Monitoring alendronate therapy with quantitative ultrasound and bone mineral density. J Clin Densitometry 2005, vol 8:3:278-286 Siris ES, Harris ST, Eastell R, Zanchetta JR Cummings SR for the Continuing Outcomes Relevant to Evista (CORE) Study. Skeletal effects of raloxifene after 8 years: Results from the Continuing Outcomes Relevant to Evista (CORE) Study. J Bone Miner Res 2005, vol 20:9;1514-1524 Lemos MC, Kotanko P, Christie PT, Harding B, Javor T, Smith C, Eastell R, Thakker RV. A novel EXT1 splice site mutation in a kindred with hereditary Multiple exostosis and osteoporosis. J Clin Endo Metab 2005, vol 90(9):5386-5392 Clowes JA, Eastell R, Peel NF. The discriminative ability of peripheral and axial bone measurements to identify proximal femoral, vertebral, distal forearm and proximal humeral fractures: A case control study. Osteo Int 2005, vol 16:12;1794-1802 Paggiosi MA, Blumsohn A, Barkmann R, Eastell R. Effect of temperature on the Longitudinal variability of quantitative ultrasound variables. J Clin Densitometry 2005, vol 8:4;436-444

Eastell R, Krege JH, Chen P, Glass EV, Reginster JY. Development of an algorithm for using P1NP to monitor treatment of patients with teriparatide. Current Medical Research and Opinions 2006, vol 22:1;61-66 Merza Z, Blumsohn A, Mah PM, Meads DM, McKenna SP, Wylie K, Eastell R, Wu F. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. Int J Androl 2006, 381-391 Veitch SW, Findlay SC, Hamer AJ, Blumsohn A, Eastell R, Ingle BM. Changes in bone mass and bone turnover following tibial shaft fracture. Osteo Int 2006, vol 17:364-372 Shetty NR, Hamer AJ, Kerry RM, Stockley I, Eastell R, Wilkinson JM. Bone remodeling around a cemented polyethylene cup. J Bone & Joint Surgery 2006, vol 88:4;455-459 Smith CM, Coombs RC, Gibson AT, Eastell R. Adaptation of the Carter method to adjust lumbar spine bone mineral content for age and body size: application to children who were born preterm. J Clin Densitometry 2006, vol 9:1;114-119 Melton LJ III, Wenger DE, Atkinson EJ, Achenback SJ, Berquist TH, Riggs BL, Jiang G, Eastell R, Influence of baseline deformity definition on subsequent vertebral fracture risk in postmenopausl women. Osteo Int 2006, vol 17:978-985 Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack, G, Adams JE, on behalf of the ATAC Trialists Group. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230). J Bone Miner Res 2006, vol 21:8; 1215-1223 Clowes JA, Peel NFA, Eastell R. Device-specific thresholds to diagnose osteoporosis at the proximal femur: an approach to interpreting peripheral bone measurements in clinical practice. Osteo Int 2006, vol 17:9;1293-1302 Kaptoge S, Armbrecht G, Felsenber D Eastell R..Reeve J. Whom to treat? The contribution of vertebral x-rays to risk-based algorithms for fracture prediction.

Results from the European Prospective Osteoporosis Study. Osteo Int 2006, vol 17:9;1369-1381 Stewart A, Felsenber D, Eastell R, Roux C, Gluer CC, Reid DM. Relationship between risk factors and QUS in a European Population: The OPUS study. Bone 2006, vol 39:609-615 Ali AM, Saleh M, Eastell R, Wigderowitz CA, Rigby AS, Yang L. Influence of bone quality on the strength of internal and external fixation of tibial plateau fractures. J Ortho Res 2006, 2080-2086 Shetty N, Hamer AJ, Stockley I, Eastell R, Wilkinson JM. Clinical and radiological outcome of total hip replacement five years after pamidronate therapy. A trial extension. J Bone Joint Surg 2006, vol 88:10;1309-15 Shetty N, Hamer AJ, Stockley I, Eastell R, Wilkinson JM. Precision of periprosthetic bone mineral density measurements using Holgic Windows versus DOS-based analysis software. J Clin Densitom 2006, vol 9:3;363-6 Rogers A. Clowes JA, Pereda CA, Eastell R. Different effects of raloxifene and estrogen on interleukin-1β and interleukin-1 receptor antagonist production using in vitro and ex vivo studies. Bone 2007, vol 40:1;105-110 Kaptoge S, Reid DM, Scheidt-Nave C, Eastell R,.Reeve J. Geographic and other determinants of BMD change in European men and women at the hip and spine. A population based study from the Network in Europe for Male Osteoporosis (NEMO). Bone 2007, vol 40:662-673

Editorials, Reviews & Book Chapters 2005/6 Eastell R, Naylor KE, Cooper AM. Pathogenesis of transplantation bone disease: A unifying hypothesis. Bone Disease of Organ Transplantation. Eds J Compston and E Shane. Elsevier Academic Press 2005:209-217 Eastell R, Riggs BL. Vitamin D and Osteoporosis. Vitamin D, 2 nd edition. Eds D Feldman, J Wesley Pike, and F H Glorieux. Elsevier Academic Press 2005: 1101-1120 Eastell R. Role of oestrogen in the regulation of bone turnover at the menarche. Journal of Endocrinology 2005; 185:223-234 Eastell R. Calcium requirements during treatment of osteoporosis in women. Preventive Nutrition, The comprehensive guide for health professionals. 3 rd edition.eds. A Bendich & R J Deckelbaum. Humana Press Inc 2005: 425-431 Ferrar L, Jiang G, Adams J, Eastell R. Identification of vertebral fractures: An Update. Osteoporosis International 2005, vol 16:7;717-728 Eastell R, Delmas PD. How to interpret surrogate markers of efficacy in osteoporosis. Letter to the Editor. J Bone Miner Res 2005, vol 20:7;1261-1262. Author reply 1263-1264 Eastell R, Hannon R. Long-term effects of aromatase inhibitors on bone. J Steroid Biochem Mol Biol 2005, vol 95(1-5):151-154 Clowes JA, Khosla S, Eastell R. Potential role of pancreatic and enteric hormones in regulating bone turnover. J Bone Miner Res 2005, vol 20:90;1497-1506 Eastell R. Management of bone health in postmenopausal women. Hormone Research2005, 64 (suppl 2):76-80 Eastell R. Osteoporosis. Medicine 2005 ; 33 :12 :61-65 Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear Factor kappab ligand : clinical utility in metabolic bone disease assessment. J Clin Endo Metab 2005, vol 90 :11;6323-6331

Shetty N, Hamer AJ, Stockley I, Eastell R, Wilkinson JM. Effect of bisphosphonates on Periprosthetic bone mineral density after total joint arthroplasty. Letter to the Editor J Bone & Joint Surgery 2005, vol 87 :11 ;2589-2590 Clowes J, Eastell R. Corticosteroid-induced osteoporosis. Osteoporosis : State of the Art. Ed : N Arden. Remedica 2006, 185-201 Eastell R. Pathogenesis of postmenopausal osteoporosis. Primer on the metabolic bone diseases and disorders of mineral metabolism. 6 th edition. Ed MJ Favus. American Society for Bone and Mineral Research 2006, 259-262. Naylor KE, Eastell R. Measurement of biochemical markers of bone formation.dynamics of bone and cartilage metabolism. 2 nd edition. Eds MJ Seibel, SP Robins, JP Bilezikian. Academic Press 2006, 529-540 Eastell R. Commentary - Does warfarin increase the risk of osteoporotic fracture? Nature Clinical Practice. Endocrinology & Metabolism 2006, vol 2 :9 ;485 Eastell R. Investigating suspected osteoporosis. Women s Health Medicine 2006, vol 3 :4 ;161-164 Eastell R. Treating Osteoporosis. Women s Health Medicine 2006, vol 3 :4,171-172 Amin S, Eastell R, Clowes JA. Risk factors for osteoporosis and fractures in men and women. Best Practice & Research Compendium Osteoporosis. Eds C Cooper & A D Woolf. Elsevier 2006, 63-77 Hannon RA, Eastell R. Bone markers and current laboratory assays. Cancer Treat Rev 2006, suppl 1 :7-14 Eastell R. Breast cancer and the risk of osteoporotic fracture : A Pardox. J Clin Endo Metab 2007, vol 92 ;1 :42-43